The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis

BACKGROUND: Age is closely related to the efficacy of treatment for non-small cell lung cancer (NSCLC) patients. Latest clinical trials have proved the better overall survival (OS) for the use of immune checkpoint inhibitors verse chemotherapy in NSCLC patients. However, we had no clear idea of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, S.-Y., Cui, H.-J., Duan, H., Peng, Y.-M., Li, Q., Sun, C.-Y., Zhang, J.-Y., Shen, W., Zhang, X., Tan, K., Jiang, X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260274/
https://www.ncbi.nlm.nih.gov/pubmed/31748961
http://dx.doi.org/10.1007/s12094-019-02241-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260274/
https://www.ncbi.nlm.nih.gov/pubmed/31748961
http://dx.doi.org/10.1007/s12094-019-02241-5

Ejemplares similares